EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing nanobody-based molecules targeting mesothelin: Exploring format, valency, size, and half-life for next-generation cancer theranostics

Remy Boisgard, Darcy MacFarland, Armelle Goubard, Rémy Castellano, Patrick Chames, Brigitte Kerfelec

Journal of Controlled Release · 2026

DOI: 10.1016/j.jconrel.2026.115129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Remy Boisgard und 5 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France. Electronic address: remy.boisgard@unibe.ch. Hauptthemen laut MEDLINE: Single-Domain Antibodies, GPI-Linked Proteins, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Centre for Scientific Research, Aix-Marseille University, Centre de Recherche en Cancérologie de Marseille.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesothelin is a tumor-associated antigen highly expressed in various cancers, with limited presence in normal tissues, making it an ideal target for cancer diagnosis and therapy. Nanobodies, small single-domain antibody fragments, possess favorable properties such as excellent tumor penetration, low immunogenicity, and versatility in design. This study engineered six anti-mesothelin nanobody-based constructs differing in format, valency, molecular weight, and half-life extension strategies, using either albumin-binding domains or Fc-fusion. All constructs were labeled with a near-infrared dye for functional evaluation. Binding affinity was measured, and tumor penetration was assessed in vitro using three-dimensional tumor models combining cancer cells and fibroblasts, as well as in vivo in xenografted mouse models. Key findings demonstrate that i) the enhancement of functional affinity is influenced by both the molecule format and the tumor cell type, ii) below a certain molecular size, bivalency can compensate size-related limitations, iii) the flexible "pearl necklace" architecture is the most suitable option for achieving optimal short-term imaging, and iv) the incorporation of half-life extension modules extends imaging and therapeutic windows, with albumin-binding-based strategies outperforming Fc-fusion in tumor biodistribution, which must be carefully balanced with specificity to maximize efficacy and minimize adverse effects. In conclusion, this study contributes to the development of more effective next-generation anti-mesothelin theranostic approaches and highlights that nanobody properties and optimal design strategies may be target specific, emphasizing the need for context-dependent development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesGPI-Linked ProteinsNeoplasmsAnimalsMesothelinHumansCell Line, TumorFemaleHalf-LifeTheranostic NanomedicineMice

Stichwörter der Autor:innen

Cancer imagingMesothelinNanobodiesNanobody-based engineeringTumor targeting

Substanzen

Single-Domain AntibodiesMesothelinGPI-Linked ProteinsMsln protein, mouse

Autor:innen und Institutionen

  • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France. Electronic address: remy.boisgard@unibe.ch.
  • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
  • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, TrGET Preclinical Platform, Marseille, France.
  • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France. Electronic address: patrick.chames@inserm.fr.
  • Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France. Electronic address: brigitte.kerfelec@inserm.fr.

Förderung

  • National Centre for Scientific Research
  • Aix-Marseille University
  • Centre de Recherche en Cancérologie de Marseille
  • Infrastructures en Biologie Santé et Agronomie
  • INSERM

Zitieren

APA

Boisgard, R., MacFarland, D., Goubard, A., Castellano, R., Chames, P., & Kerfelec, B. (2026). Optimizing nanobody-based molecules targeting mesothelin: Exploring format, valency, size, and half-life for next-generation cancer theranostics. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115129

Vancouver

Boisgard R, MacFarland D, Goubard A, Castellano R, Chames P, Kerfelec B. Optimizing nanobody-based molecules targeting mesothelin: Exploring format, valency, size, and half-life for next-generation cancer theranostics. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115129

BibTeX
@article{Boisgard2026,
  author = {Boisgard, Remy and MacFarland, Darcy and Goubard, Armelle and Castellano, Rémy and Chames, Patrick and Kerfelec, Brigitte},
  title = {Optimizing nanobody-based molecules targeting mesothelin: Exploring format, valency, size, and half-life for next-generation cancer theranostics},
  journal = {Journal of Controlled Release},
  year = {2026},
  doi = {10.1016/j.jconrel.2026.115129}
}
Kostenlos starten →